Core Viewpoint - The annual general meeting of Jilin Xidian Pharmaceutical Technology Development Co., Ltd. was held on May 15, 2025, where all proposed resolutions were approved without any objections from shareholders [1][2]. Meeting Details - The meeting was held on May 15, 2025, at 14:00, combining on-site and online voting methods [2][3]. - A total of 39 shareholders attended, representing 28,200,928 shares, which is 36.8665% of the total voting shares [3][4]. Voting Results - The following resolutions were passed with significant majority votes: 1. 2024 Annual Board Work Report: 99.9773% approval [6][8]. 2. 2024 Annual Supervisory Board Work Report: 99.9773% approval [8][9]. 3. 2024 Annual Report: 99.9773% approval [10][11]. 4. 2024 Financial Settlement Report: 99.9773% approval [12][13]. 5. 2024 Profit Distribution Plan: 99.9773% approval [14][15]. 6. Appointment of 2025 Accounting Firm: 99.9773% approval [16][17]. 7. 2025 Director Compensation Plan: 99.9773% approval [18][19]. 8. 2025 Supervisor Compensation Plan: 99.9773% approval [20][21]. 9. Amendment to Articles of Association: Passed as a special resolution with over two-thirds approval [22][23]. 10. Amendment to Company Policies: Passed as a special resolution with over two-thirds approval [23]. Legal Opinion - The legal opinion provided by Beijing Hairun Tianrui Law Firm confirmed that the meeting's procedures, attendance, and voting methods complied with relevant laws and regulations [24][26][48].
吉林省西点药业科技发展股份有限公司 2024年年度股东大会决议公告